Unlicensed drug

#Early access #Rare disease #Regulatory #Unlicensed drug

Bridging the gap between unlicensed medicines and unmet need

Suzanne Aitken, Senior Vice President of Managed Access at Clinigen, discusses the benefits of unlicensed medicines (ULMs) and why regulators and the industry need to do more to improve patient access to these therapies.  The pharmaceutical industry is constantly changing. However, an unwavering problem is the constant unmet need facing… Read More

#Exclusive Content #Opinion

#Clinigen #Early access #Education #Rare disease #Unlicensed drug

A third of rare disease patients unaware of early access programmes

One-third (32%) of rare disease patients are not aware they can access unlicensed medicines through Early Access Programmes, new research has revealed. However, two-thirds (68%) of patients are comfortable receiving medicines before they’re licensed through their country’s healthcare system. The new data was released… Read More

#News

Doctor writing a prescription
#Drug repurposing #EMA #FDA #MHRA #Regulatory #Unlicensed drug

Unlicensed and off-label drugs: What do we know?

Following the death of a cancer patient after they were given an unlicensed drug, Diana Spencer unpacks the practice of prescribing unlicensed and off-label medicines. This month, a cancer patient died and three others were hospitalised in the UK after they were administered an unlicensed version of the chemotherapy drug… Read More

#Exclusive Content #Regulatory

Patients receiving chemotherapy
#Adverse event #Cancer treatment #Chemotherapy #MHRA #NHS #Unlicensed drug

Patient dies after receiving unlicensed drug

A cancer patient died and three others were hospitalised in the UK after they were administered an unlicensed version of chemotherapy cabazitaxel. According to The Guardian, which reported on the incident, the problem was caused by an issue at private healthcare company Sciensus’… Read More

#News #Trending News